This research group is looking for you!
Cancer immunotherapy has revolutionized the treatment of cancer patients and promises to be the biggest game changer in modern medicine. Immune responses in general are self-limiting to avoid unnecessary tissue destruction when combatting a pathogenic invader. This regulatory circuit is well controlled and balances effective pathogen defenses with the maintenance of normal tissue functions. Immunotherapy seeks to drive immune responses against cancer by interfering with the normal regulatory functions of immunity. These “checkpoint inhibitors” are now used to treat several cancers, but were particularly successful in metastatic melanoma, where patients have seen remarkable and durable responses. However, not all patients benefit from these groundbreaking treatments, and given the 3-4 months required to assess response (as well as the high expense and incidence of adverse events), it is essential to personalize therapeutic options according to the individual patient. In this way, we hope to identify “predictive biomarkers” that will more effectively optimize therapy options and increase the chance of controlling the disease for each patient.
We have assembled a unique and innovative consortium that integrates an advanced biomarker discovery pipeline through the combination of detailed and comprehensive measurements of patient blood profiles, as well as the quantitative analysis of radiology images and machine learning approaches. We will use all these data to develop better predictive and prognostic biomarkers and treatment algorithms for cancer immunotherapy, with the goal of ultimately extending the benefit of the latest cancer drugs to as many patients as possible. The candidate will apply and develop computational approaches to identify therapy response associated cell subsets and instruct further in-depth experiments for these cell subsets. Upon validation in independent patient cohorts, this information will then be used to stratify patients prior to immunotherapy to maximize the therapeutic impact and to minimize adverse effects as well as to provide new personalized therapeutic targets for immune-intervention across the Swiss wide patient population.
28-02-2024
Bitte sage uns, wo du ähnliche Stellenanzeigen suchst und vergiss nicht deine E-Mail Adresse anzugeben!